Comparison of the digene hybrid capture 2 assay and Roche AMPLICOR and LINEAR ARRAY human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal Pap smear results

Journal of Clinical Microbiology

Volumn 45, Issue 7, 2007, Pages 2130-2137

  Stevens, Matthew P ^a   Garland, Suzanne M ^a,b   Rudland, Elice ^a   Tan, Jeffrey ^a,b   Quinn, Michael A ^a,b   Tabrizi, Sepehr N ^a,b  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; GENOTYPE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; NONHUMAN; PAPANICOLAOU TEST; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; VIRUS IDENTIFICATION; VIRUS INFECTION; WART VIRUS;

ALPHAPAPILLOMAVIRUS; DNA, VIRAL; FEMALE; GENOTYPE; HUMANS; PAPILLOMAVIRUS INFECTIONS; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

HUMAN PAPILLOMAVIRUS;

EID: 34547631578     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.02438-06     Document Type: Article

References (49)

1. Bosch, F. X., M. M. Manos, N. Munoz, M. Sherman, A. M. Jansen, J. Peto, M. H. Schiffman, V. Moreno, R. Kurman, and K. V. Shah. 1995. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J. Natl. Cancer Inst. 87:796-802.
2. Bosch, F. X., A. Lorincz, N. Munoz, C. J. Meijer, and K. V. Shah. 2002. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 55:244-265.
3. Burk, R. D., P. Kelly, J. Feldman, J. Bromberg, S. H. Vermund, J. A. DeHovitz, and S. H. Landesman. 1996. Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors. Sex Transm. Dis. 23:333-341.
4. Carozzi, F. M., M. Confortini, S. Cecchini, S. Bisanzi, M. P. Cariaggi, G. Pontenani, M. R. Raspollini, C. Sani, M. Zappa, and S. Ciatto. 2005. Triage with human papillomavirus testing of women with cytologic abnormalities prompting referral for colposcopy assessment. Cancer 105:2-7.
5. Castle, P. E., A. T. Lorincz, I. Mielzynska-Lohnas, D. R. Scott, A. G. Glass, M. E. Sherman, J. E. Schussler, and M. Schiffman. 2002. Results of human papillomavirus DNA testing with the hybrid capture 2 assay are reproducible. J. Clin. Microbiol. 40:1088-1090.
6. Castle, P. E., M. Schiffman, R. D. Burk, S. Wacholder, A. Hildesheim, R. Herrero, M. C. Bratti, M. E. Sherman, and A. Lorincz. 2002. Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol. Biomarkers Prev. 11:1394-1399.
7. Clifford, G. M., J. S. Smith, M. Plummer, N. Munoz, and S. Franceschi. 2003. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br. J. Cancer 88:63-73.
8. Cox, J. T., A. T. Lorincz, M. H. Schiffman, M. E. Sherman, A. Cullen, and R. J. Kurman. 1995. Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance. Am. J. Obstet. Gynecol. 172:946-954.
9. Cuzick, J., A. Szarewski, G. Terry, L. Ho, A. Hanby, P. Maddox, M. Anderson, G. Kocjan, S. T. Steele, and J. Guillebaud. 1995. Human papillomavirus testing in primary cervical screening. Lancet 345:1533-1536.
10. de Roda Husman, A. M., J. M. Walboomers, A. J. van den Brule, C. J. Meijer, and P. J. Snijders. 1995. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J. Gen. Virol. 76:1057-1062.
11. de Villiers, E. M., C. Fauquet, T. R. Broker, H. U. Bernard, and H. zur Hausen. 2004. Classification of papillomaviruses. Virology 324:17-27.
12. Gravitt, P. E., C. L. Peyton, R. J. Apple, and C. M. Wheeler. 1998. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J. Clin. Microbiol. 36:3020-3027.
13. Gravitt, P. E., C. L. Peyton, T. Q. Alessi, C. M. Wheeler, F. Coutlee, A. Hildesheim, M. H. Schiffman, D. R. Scott, and R. J. Apple. 2000. Improved amplification of genital human papillomaviruses. J. Clin. Microbiol. 38:357-361.
14. Ho, G. Y., R. D. Burk, S. Klein, A. S. Kadish, C. J. Chang, P. Palan, J. Basu, R. Tachezy, R. Lewis, and S. Romney. 1995. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J. Natl. Cancer Inst. 87:1365-1371.
15. Jacobs, M. V., P. J. Snijders, A. J. van den Brule, T. J. Helmerhorst, C. J. Meijer, and J. M. Walboomers. 1997. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J. Clin. Microbiol. 35:791-795.
16. Kjaer, S. K., A. J. van den Brule, G. Paull, E. I. Svare, M. E. Sherman, B. L. Thomsen, M. Suntum, J. E. Bock, P. A. Poll, and C. J. Meijer. 2002. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 325:572-576.
17. Kjaer, S., E. Hogdall, K. Frederiksen, C. Munk, A. van den Brule, E. Svare, C. Meijer, A. Lorincz, and T. Iftner. 2006. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res. 66:10630-10636.
18. Kleter, B., L. J. van Doorn, J. ter Schegget, L. Schrauwen, K. van Krimpen, M. Burger, B. ter Harmsel, and W. Quint. 1998. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am. J. Pathol. 153:1731-1739.
19. Lorincz, A. T., and R. M. Richart. 2003. Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs. Arch. Pathol. Lab. Med. 127:959-968.
20. Monsonego, J., J. M. Bohbot, G. Pollini, C. Krawec, C. Vincent, I. Merignargues, F. Haroun, P. Sednaoui, L. Monfort, R. Dachez, and K. Syrjanen. 2005. Performance of the Roche AMPLICOR human papillomavirus (HPV) test in prediction of cervical intraepithelial neoplasia (CIN) in women with abnormal PAP smear. Gynecol. Oncol. 99:160-168.
21. Munoz, N., and F. X. Bosch. 1996. The causal link between HPV and cervical cancer and its implications for prevention of cervical cancer. Bull. Pan. Am. Health Organ. 30:362-377.
22. Munoz, N., F. X. Bosch, S. de Sanjose, R. Herrero, X. Castellsague, K. V. Shah, P. J. Snijders, C. J. Meijer, et al. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348:518-527.
23. Munoz, N., X. Castellsague, A. B. de Gonzalez, and L. Gissmann. 2006. HPV in the etiology of human cancer. Vaccine 24-S3:S1-S10.
24. Perrons, C., B. Kleter, R. Jelley, H. Jalal, W. Quint, and R. Tedder. 2002. Detection and genotyping of human papillomavirus DNA by SPF10 and MY09/11 primers in cervical cells taken from women attending a colposcopy clinic. J. Med. Virol. 67:246-252.
25. Perrons, C., R. Jelley, B. Kleter, W. Quint, and N. Brink. 2005. Detection of persistent high-risk human papillomavirus infections with hybrid capture II and SPF10/LiPA. J. Clin. Virol. 32:278-285.
26. Peyton, C. L., M. Schiffman, A. T. Lorincz, W. C. Hunt, I. Mielzynska, C. Bratti, S. Eaton, A. Hildesheim, L. A. Morera, A. C. Rodriguez, R. Herrero, M. E. Sherman, and C. M. Wheeler. 1998. Comparison of PCR- and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies. J. Clin. Microbiol. 36:3248-3254.
27. Poljak, M., A. Brencic, K. Seme, A. Vince, and I. J. Marin. 1999. Comparative evaluation of first- and second-generation Digene hybrid capture assays for detection of human papillomaviruses associated with high or intermediate risk for cervical cancer. J. Clin. Microbiol. 37:796-797.
28. Poljak, M., I. J. Marin, K. Seme, and A. Vince. 2002. Hybrid Capture II HPV Test detects at least 15 human papillomavirus genotypes not included in its current high-risk probe cocktail. J. Clin. Virol. 25-S. 3:S89-S97.
29. Poljak, M., K. Fujs, K. Seme, B. J. Kocjan, and E. Vrtacnik-Bokal. 2005. Retrospective and prospective evaluation of the Amplicor HPV test for detection of 13 high-risk human papillomavirus genotypes on 862 clinical samples. Acta Dermatovenerol. Alp. Panonica Adriat. 14:147-152.
30. Remmink, A. J., J. M. Walboomers, T. J. Helmerhorst, F. J. Voorhorst, L. Rozendaal, E. K. Risse, C. J. Meijer, and P. Kenemans. 1995. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int. J. Cancer 61:306-311.
31. Rozendaal, L., J. Westerga, J. C. van der Linden, J. M. Walboomers, F. J. Voorhorst, E. K. Risse, M. E. Boon, and C. J. Meyer. 2000. PCR based high risk HPV testing is superior to neural network based screening for predicting incident CIN III in women with normal cytology and borderline changes. J. Clin. Pathol. 53:606-611.
32. Sandri, M. T., P. Lentati, E. Benini, P. Dell'Orto, L. Zorzino, F. M. Carozzi, P. Maisonneuve, R. Passerini, M. Salvatici, C. Casadio, S. Boveri, and M. Sideri. 2006. Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples. J. Clin. Microbiol. 44:2141-2146.
33. Schiffman, M. H., H. M. Bauer, R. N. Hoover, A. G. Glass, D. M. Cadell, B. B. Rush, D. R. Scott, M. E. Sherman, R. J. Kurman, and S. Wacholder. 1993. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J. Natl. Cancer Inst. 85:958-964.
34. Schiffman, M., C. M. Wheeler, P. E. Castle, et al. 2002. Human papillomavirus DNA remains detectable longer than related cervical cytologic abnormalities. J. Infect. Dis. 186:1169-1172.
35. Snijders, P. J., A. J. van den Brule, and C. J. Meijer. 2003. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J. Pathol. 201:1-6.
36. Soderlund-Strand, A., P. Rymark, P. Andersson, J. Dillner, and L. Dillner. 2005. Comparison between the Hybrid Capture II test and a PCR-based human papillomavirus detection method for diagnosis and posttreatment follow-up of cervical intraepithelial neoplasia. J. Clin. Microbiol. 43:3260-3266.
37. Stevens, M. P., S. M. Garland, and S. N. Tabrizi. 2006. Human papillomavirus genotyping using a modified linear array detection protocol. J. Virol. Methods 135:124-126.
38. Stevens, M. P., E. Rudland, S. M. Garland, and S. N. Tabrizi. 2006. Assessment of MagNA Pure LC extraction system for detection of human papillomavirus (HPV) DNA in PreservCyt samples by the Roche AMPLICOR and LINEAR ARRAY HPV tests. J. Clin. Microbiol. 44:2428-2433.
39. Stevens, M. P., S. N. Tabrizi, M. A. Quinn, and S. M. Garland. 2006. Human papillomavirus genotype prevalence in cervical biopsies from women diagnosed with cervical intraepithelial neoplasia or cervical cancer in Melbourne, Australia. Int. J. Gynecol. Cancer 16:1017-1024.
40. Tabrizi, S. N., M. Stevens, S. Chen, E. Rudland, J. R. Kornegay, and S. M. Garland. 2005. Evaluation of a modified reverse line blot assay for detection and typing of human papillomavirus. Am. J. Clin. Pathol. 123:896-899.
41. Terry, G., L. Ho, P. Londesborough, J. Cuzick, I. Mielzynska-Lohnas, and A. Lorincz. 2001. Detection of high-risk HPV types by the hybrid capture 2 test. J. Med. Virol. 65:155-162.
42. The Atypical Low-Grade Squamous Intraepithelial Lesions Triage Study Group. 2000. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. J. Natl. Cancer Inst. 92:397-402.
43. van Doom, L. J., A. Molijn, B. Kleter, W. Quint, and B. Colau. 2006. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J. Clin. Microbiol. 44:3292-3298.
44. van Ham, M. A., J. M. Bakkers, G. K. Harbers, W. G. Quint, L. F. Massuger, and W. J. Melchers. 2005. Comparison of two commercial assays for detection of human papillomavirus (HPV) in cervical scrape specimens: validation of the Roche AMPLICOR HPV test as a means to screen for HPV genotypes associated with a higher risk of cervical disorders. J. Clin. Microbiol. 43:2662-2667.
45. van Hamont, D., M. A. van Ham, J. M. Bakkers, L. F. Massuger, and W. J. Melchers. 2006. Evaluation of the SPF10-INNO LiPA human papillomavirus (HPV) genotyping test and the Roche linear array HPV genotyping test. J. Clin. Microbiol. 44:3122-3129.
46. Vince, A., N. Kutela, J. Iscic-Bes, V. Harni, M. Ivanisevic, Z. Sonicki, Z. Culig, and M. Poljak. 2002. Clinical utility of molecular detection of human papillomavirus in cervical samples by hybrid capture technology. J. Clin. Virol. 25(S.3):S109-S112.
47. Walboomers, J. M., M. V. Jacobs, M. M. Manos, F. X. Bosch, J. A. Kummer, K. V. Shah, P. J. Snijders, J. Peto, C. J. Meijer, and N. Munoz. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189:12-19.
48. Wallin, K. L., F. Wiklund, T. Angstrom, F. Bergman, U. Stendahl, G. Wadell, G. Hallmans, and J. Dillner. 1999. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N. Engl. J. Med. 341:1633-1638.
49. Zielinski, G. D., P. J. Snijders, L. Rozendaal, F. J. Voorhorst, A. P. Runsink, F. A. de Schipper, and C. J. Meijer. 2001. High-risk HPV testing in women with borderline and mild dyskaryosis: long-term follow-up data and clinical relevance. J. Pathol. 195:300-306.